Press Release
Arcadia Biosciences and Shriram Bioseed Reach Milestone in Developing Extended Shelf Life Tomatoes
-- Non-GM tomato varieties to reduce post-harvest damage and waste --
Bioseed has field tested Arcadia’s ESL technology in multiple tomato hybrid backgrounds in multiple locations and seasons. Significant and consistent improvements in field yield and fruit quality, such as firmness, shelf life and color development, were observed. These new hybrids are in the pre-commercial, wide area field testing stage with anticipated launch in 2019.
Because of their perishable nature, many harvested fresh fruits and
vegetables spoil and become food waste instead of being consumed.
According to the
Using a non-GM advanced screening and breeding technique called TILLING, Arcadia identified genetic variations that allow tomatoes to fully ripen on the vine, yet still remain durable enough to survive the packing and shipping process.
“These new varieties will reduce waste and spoilage in the production cycle while ensuring that the produce is fully ripe, better tasting, and still fresh when it reaches consumers,” said Raj Ketkar, president and CEO of Arcadia. “This development is a significant commercial milestone in advancing Arcadia’s ESL tomato technology that adds value throughout the tomato supply chain, from farm to consumers.”
“This trait is especially valuable in a country like
Arcadia’s ESL technology was developed in part under a
About
About Shriram Bioseed
Shriram Bioseed, the hybrid seed business of
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements relating to Arcadia’s expectations regarding the
commercial release date of extended shelf life tomatoes and the reduced
waste, spoilage, characteristics and value that will be provided by
these tomatoes. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially, and
reported results should not be considered as an indication of future
performance. These risks and uncertainties include, but are not limited
to: Arcadia’s and its partners’ and affiliates’ ability to develop
commercial products incorporating their traits, and complete the
regulatory review process for such products; Arcadia’s compliance with
laws and regulations that impact Arcadia’s business, and changes to such
laws and regulations; Arcadia’s future capital requirements and ability
to satisfy its capital needs; and the other risks set forth in Arcadia’s
filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20180719005255/en/
Source:
Arcadia Biosciences
Jeff Bergau
+1-312-217-0419
jeff.bergau@arcadiabio.com
or
Shriram
Bioseed
Aman Pannu
+91 98990 78610
amanpannu@dcmshriram.com